

| | | | |
|---|--|--|-----------------|
| INFORMATION DISCLOSURE STATEMENT | | Docket: 4239-62489 | App: _____ |
| | | Applicant: Ken-Ichi Hanada and James C. Yang | |
| BY APPLICANT <i>KAC</i> JAN 30 2006 | | Filed: Herewith | Art Unit: _____ |



| Init.* | Number | Date | Name | Class | Sub | Filed |
|------------|-----------|------------|-----------------|-------|-----|-------|
| <i>KAC</i> | 5,155,217 | 10/13/1992 | Goldfarb et al. | | | |
| | 5,192,537 | 3/9/1993 | Osband | | | |
| | 5,238,916 | 8/24/1993 | Goldfarb et al. | | | |
| | 5,759,535 | 6/2/1998 | Cohen | | | |
| | 5,837,233 | 11/17/1998 | Granger | | | |
| | 5,874,254 | 2/23/1999 | Imamura et al. | | | |
| | 5,919,459 | 7/6/1999 | Nacy et al. | | | |
| | 5,935,818 | 8/10/1999 | Israeli et al. | | | |
| ✓ | 5,939,526 | 8/17/1999 | Gaugler et al. | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | Number | Date | Country | Class | Sub | |
|------------|-------------|----------|---------|-------|-----|--|
| <i>KAC</i> | 10-017599 | 20-01-98 | Japan | | | |
| | WO 90/12597 | 01.11.90 | PCT | | | |
| | WO 97/30155 | 21.08.97 | PCT | | | |
| | WO 97/33602 | 18.09.97 | PCT | | | |
| | WO 98/32456 | 30.07.98 | PCT | | | |
| ✓ | WO 99/13912 | 25.03.99 | PCT | | | |

EXAMINER: *John J. Camella* DATE *4/16/2006*

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

| INFORMATION DISCLOSURE STATEMENT | | Docket: 4239-62489 | App: _____ | | | | |
|--|--|---|-----------------|---------|----------|----------|--|
| BY APPLICANT | | Applicant: Ken-Ichi Hanada and James C. Yang | | | | | |
| | | Filed: Herewith | Art Unit: _____ | | | | |
| FOR RELATED PATENT DOCUMENTS | | | | | | | |
| | | Number | Date | Country | Class | Sub | |
| <i>KAC</i> | | WO 99/55861 | 04.11.99 | PCT | <i>P</i> | <i>S</i> | |
| <i>KAC</i> | | WO 00/24756 | 04.05.00 | PCT | <i>P</i> | <i>S</i> | |
| OTHER DOCUMENTS | | | | | | | |
| <i>KAC</i> | | Genbank Accession No. NM_004464, 18 October 2005. | | | | | |
| | | Genbank Accession No. NP_004455, 18 October 2005. | | | | | |
| | | Genbank Accession No. M23534 M21617, 15 May 1995 | | | | | |
| | | Genbank Accession No. M37825, 22 August 1996. | | | | | |
| | | Albino et al., "Induction of Growth Factor RNA Expression in Human Malignant Melanoma: Markers of Transformation," <i>Cancer Res.</i> 51: 4815-4820 (1991). <i>KAC 4/14/2006</i> | | | | | |
| | | Altorki et al., "Characterization of Cell Lines Established from Human Gastric-Esophageal Adenocarcinomas," <i>Cancer</i> 72:649-657 (1993). | | | | | |
| | | Belldegrun et al., "Human Renal Carcinoma Line Transfected With Interleukin-2 and/or Interferon α Gene(s): Implications for Live Cancer Vaccines," <i>J. Natl. Cancer Inst.</i> 85:207-216 (1993). | | | | | |
| EXAMINER: <i>John A. Gamble</i> | | DATE <i>4/14/2006</i> | | | | | |
| *Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy. | | | | | | | |

| | | | | |
|--|--|--|--|-----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT JAN 30 2006 | | | Docket: 4239-62489 | App: _____ |
| | | | Applicant: Ken-Ichi Hanada and James C. Yang | |
| | | | Filed: Herewith | Art Unit: _____ |
| RELEVANT DOCUMENTS | | | | |
| <i>KAI</i> | | | Bernhard et al., "Cellular Immune Response to Human Renal-Cell Carcinomas: Definition of a Common Antigen Recognized by HLA-A2-Restricted Cytotoxic T-Lymphocyte (CTL) Clones," <i>Int. J. Cancer</i> 59:837-842 (1994). | |
| | | | | |
| | | | Bernhard et al., "Tumor Associated Antigens in Human Renal Cell Carcinoma: MHC Restricted Recognition by Cytotoxic T Lymphocytes," <i>Tissue Antigens</i> 48:22-31 (1996). | |
| | | | | |
| | | | Brandle et al., "A Mutated HLA-A2 Molecule Recognized by Autologous Cytotoxic T Lymphocytes on a Human Renal Cell Carcinoma," <i>J. Exp. Med.</i> 183:2501-2508 (1996). | |
| | | | | |
| | | | Brossart et al., "Her-2/neu-Derived Peptides are Tumor-Associated Expressed by Human Renal Cell and Colon Carcinoma Lines and are Recognized by <i>in Vitro</i> Induced Specific Cytotoxic T Lymphocytes," <i>Cancer Res.</i> 58:732-736 (1998). | |
| | | | | |
| | | | Brouwenstijn et al., "Renal-Cell Carcinoma-Specific Lysis by Cytotoxic T-lymphocyte Clones Isolated from Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes," <i>Int. J. Cancer</i> 68:177-182 (1996). | |
| | | | | |
| | | | Brouwenstijn et al., "Definition of Unique and Shared T-Cell Defined Tumor Antigens in Human Renal Cell Carcinoma," <i>J. Immunother.</i> 21:427-434 (1998). | |
| | | | | |
| | | | Caignard et al., " <i>In Situ</i> Demonstration of Renal-Cell-Carcinoma-Specific T-Cell Clones," <i>Int. J. Cancer</i> 66:564-570 (1996). | |
| | | | | |
| | | | Chen et al., "Genomic Cloning and Localization of CTAG, a Gene Encoding an Autoimmunogenic Cancer-Testis Antigen NY-ESO-1, to Human Chromosome Xq28," <i>Cytogenet. Cell Genet.</i> 79:237-240 (1997). | |
| | | | | |
| <i>✓</i> | | | Chen et al., "A Testicular Antigen Aberrantly Expressed in Human Cancers Detected by Autologous Antibody Screening," <i>Proc. Natl. Sci. USA</i> 94:1914-1918 (1997). | |
| | | | | |
| EXAMINER: <i>John A. Gamble</i> | | | DATE <i>4/14/2006</i> | |
| *Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy. | | | | |

| | | | | |
|---|--|--|---|------------|
| INFORMATION DISCLOSURE STATEMENT | | | Docket: 4239-62489 | App: _____ |
| BY APPLICANT | | | JAN 30 2006 PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE | |
| OTHER DOCUMENTS | | | | |
| <i>JKL</i> | | | Clements et al., "Activation of Fibroblast Growth Factor (FGF) Receptors by Recombinant Human FGF-5," <i>Oncogene</i> 8:1311-1316 (1993). | |
| | | | | |
| | | | Cullen et al., "Growth Factor Messenger RNA Expression by Human Breast Fibroblasts from Benign and Malignant Lesions," <i>Cancer Res.</i> 51:4978-4985 (1991). | |
| | | | | |
| | | | Eisenthal et al., "Human Tumor Cells, Modified by a Novel Pressure/Crosslinking Methodology, Promote Autologous Lymphocyte Proliferation and Modulate Cytokine Secretion," <i>Cancer Immunol. Immunother.</i> 46:304-310 (1998). | |
| | | | | |
| | | | Gaugler et al., "A New Gene Coding for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on a Human Renal Carcinoma," <i>Immunogenetics</i> 44:323-330 (1996). | |
| | | | | |
| | | | Goldfarb et al., "Expression and Possible Functions of the FGF-5 Gene," <i>Ann. NY Acad. Sci.</i> 638:38-52 (1991). | |
| | | | | |
| | | | Haub et al., "Expression of the Fibroblast Growth Factor-5 Gene in the Mouse Embryo," <i>Development</i> 112:397-406 (1991). | |
| | | | | |
| | | | Hannon et al., "Differentially Expressed Fibroblast Growth Factors Regulate Skeletal Muscle Development through Autocrine and Paracrine Mechanisms," <i>J. Cell Biol.</i> 132:1151-1159 (1996). | |
| | | | | |
| | | | Hughes et al., "Evidence that Fibroblast Growth Factor 5 is a Major Muscle-Derived Survival Factor for Cultured Spinal Motoneurons," <i>Neuron</i> 10:369-377 (1993). | |
| | | | | |
| <i>✓</i> | | | Jäger et al., "Simultaneous Humoral and Cellular Immune Response against Cancer-Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2-Binding Peptide Epitopes," <i>J. Exp. Med.</i> 187:265-270 (1998). | |
| | | | | |
| EXAMINER: <i>John J. Canella</i> | | | DATE <i>4/14/2006</i> | |
| <p>*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.</p> | | | | |

| | | | | |
|---|--|--|---|-----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Docket: 4239-62489 | App: _____ |
| | | | JAN 30 2006 U.S. PATENT AND TRADEMARK OFFICE | |
| | | | Applicant: Ken-Ichi Hanada and James C. Yang | |
| | | | Filed: Herewith | Art Unit: _____ |
| OTHER DOCUMENTS | | | | |
| <p><i>XAC</i></p> <p>Jäger et al., "Strategies for the Development of Vaccines to Treat Breast Cancer," <i>Recent Results Cancer Res.</i> 152:94-102 (1998).</p> | | | | |
| <p>Kirkin et al., "Melanoma-Associated Antigens Recognized by Cytotoxic T Lymphocytes," <i>APMIS</i> 106:665-679 (1998).</p> | | | | |
| <p>Kitaoka et al., "Distribution of FGF-5 in the Rhesus Macaque Retina," <i>Invest. Ophthalmol. Vis. Sci.</i> 35:3189-3198 (1994).</p> | | | | |
| <p>Kornmann et al., "Fibroblast Growth Factor-5 Stimulates Mitogenic Signaling and is Overexpressed in Human Pancreatic Cancer: Evidence for Autocrine and Paracrine Actions," <i>Oncogene</i> 15:1417-1424 (1997).</p> | | | | |
| <p>Lee et al., "NY-ESO-1 May be a Potential Target for Lung Cancer Immunotherapy," <i>Cancer J. Sci. Am.</i> 5:20-25 (1999).</p> | | | | |
| <p>Neumann et al., "Heterogeneous Expression of the Tumor-Associated Antigens RAGE-1, PRAME, and Gycoprotein 75 in Human Renal Cell Carcinoma: Candidates for T-Cell-Based Immunotherapies?," <i>Cancer Res.</i> 58:4090-4095 (1998).</p> | | | | |
| <p>Parmiani, "Future Perspectives in Specific Immunotherapy of Melanoma," <i>Eur. J. Cancer</i> 34:S42-S47 (1998).</p> | | | | |
| <p>Ramakrishna et al., "Generation and Phenotypic Characterization of New Human Ovarian Cancer Cell Lines with the Identification of Antigens Potentially Recognizable by HLA-Restricted Cytotoxic T Cells," <i>Int. J. Cancer</i> 73:143-150 (1997).</p> | | | | |
| <p>Rivoltini et al., "Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity," <i>Critical Rev. Immunol.</i> 18:55-63 (1998).</p> | | | | |
| EXAMINER: | | | DATE <i>4/14/2006</i> | |
| <p>*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.</p> | | | | |

| | | | | |
|--|-------------------------|--|--|------------------|
| INFORMATION DISCLOSURE STATEMENT | | | Docket: 4239-62489 | App: _____ |
| BY APPLICANT | | | Applicant: Ken-Ichi Hanada and James C. Yang | |
| | | | Filed: Herewith | Art Unit: _____ |
| OTHER DOCUMENTS | | | | |
| <i>KAC</i> | | | Wang et al., "A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames," <i>J. Immunol.</i> 161:3596-3606 (1998). | |
| | | | | |
| | | | Weidmann et al., "Evidence for Oligoclonal T-Cell Response in a Metastasis of Renal Cell Carcinoma Responding to Vaccination with Autologous Tumor Cells and Transfer of <i>in Vitro</i> -Sensitized Vaccine-Draining Lymph Node Lymphocytes," <i>Cancer Res.</i> 53:4745-4749 (1993). | |
| | | | Werner et al., "Fibroblast Growth Factor 5-Proto-Oncogene is Expressed in Normal Human Fibroblasts and Induced by Serum Growth Factors," <i>Oncogene</i> 6:2137-2144 (1991). | |
| | | | Wilson et al., "Cross-Recognition of Two Middle T Protein Epitopes by Immunodominant Polyoma Virus-Specific CTL," <i>J. Immunol.</i> 162:3933-3941 (1999). | |
| | | | Yamanaka et al., "Expression of Fibroblast Growth Factors in Human Non-Papillary Renal Cell Carcinoma: Correlation with Tumor Progression," <i>International J. of Clin. Oncol.</i> 1999 (Abstract). | |
| | | | Yoshimura et al., "Messenger Ribonucleic Acids for Fibroblast Growth Factors and Their Receptor in Bladder and Renal Cell Carcinoma Cell Lines," <i>Cancer Lett.</i> 103:91-97 (1996). | |
| | | | Zhan et al., "The Human FGF-5 Oncogene Encodes a Novel Protein Related to Fibroblast Growth Factors," <i>Mol. Cell. Biol.</i> 8:3487-3495 (1988). | |
| | | | | |
| | | | | |
| EXAMINER: | <i>Norma J. Canille</i> | | DATE | <i>4/14/2006</i> |
| *Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy. | | | | |